Sage Therapeutics. has filed a patent for Compound 1 and its pharmaceutically acceptable salts or compositions. The patent aims to treat CNS related disorders such as tremor, depression, and anxiety disorder. Additionally, the patent includes methods to improve the effectiveness and bioavailability of Compound 1. GlobalData’s report on Sage Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Sage Therapeutics, Anti-inflammatory anesthetics was a key innovation area identified from patents. Sage Therapeutics's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of cns related disorders with compound 1
A recently filed patent (Publication Number: US20230310459A1) describes a method for treating central nervous system (CNS)-related disorders in subjects. The method involves administering a compound, which is effective in treating the disorder, to the subject along with food. The compound is defined by a specific formula.
The patent claims specify various aspects of the method. Claim 121 states that the compound should be administered substantially contemporaneously with food. Claim 122 further clarifies that the area under the curve (AUC) value for the compound should be AUC0-t, which represents the AUC from the time of dosing to the last quantifiable concentration.
The CNS-related disorders that can be treated using this method include GABA-related diseases or disorders, mood disorders, movement disorders, postpartum depression, major depressive disorder, essential tremor, Parkinson's disease, anxiety disorders (such as generalized anxiety disorder), bipolar disorder, and tinnitus. Claim 125 specifies that the therapeutically effective amount of the compound is between about 25 mg to about 50 mg.
The method also considers the type of food consumed along with the compound. Claim 126 states that the food can be a high fat meal. Additionally, the compound can be administered once a day for 14 days, as mentioned in claim 127.
The compound itself can exist in a specific form called Form C, as stated in claim 128. Furthermore, claim 129 specifies that the therapeutically effective amount of the compound can be in a solid dosage form.
Another method described in the patent involves administering the compound within 60 minutes before or after ingesting food, as mentioned in claim 130. The other claims related to this method are similar to the previous method, including the AUC value, CNS-related disorders, therapeutically effective amount, food type, administration frequency, compound form, and dosage form.
The patent also includes an article of manufacture, as described in claim 139, which comprises a therapeutically effective amount of the compound. This article can be in the form of Form C, as stated in claim 140.
In summary, the patent describes methods for treating CNS-related disorders by administering a specific compound along with food. The compound can be effective in treating various disorders, and its administration can be optimized by considering factors such as the type of food consumed and the timing of administration. The compound can exist in a specific form and can be formulated into a solid dosage form. The patent also includes an article of manufacture comprising the compound.
To know more about GlobalData’s detailed insights on Sage Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
